IL108811A - Immunoassay reagents, kits and methods - Google Patents

Immunoassay reagents, kits and methods

Info

Publication number: IL108811A
Authority: IL; Israel
Prior art keywords: urine; sle; extracellular matrix; antibodies; lupus erythematosus
Prior art date: 1994-03-01

Application number

IL108811A

Other languages

English (en)

Other versions

IL108811A0 (en

Original Assignee

Hadasit Med Res Service

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-01

Filing date

1994-03-01

Publication date

1998-06-15

1994-03-01 Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service

1994-03-01 Priority to IL108811A priority Critical patent/IL108811A/en

1994-06-24 Publication of IL108811A0 publication Critical patent/IL108811A0/xx

1995-02-27 Priority to EP95102740A priority patent/EP0670495B1/de

1995-02-27 Priority to AT95102740T priority patent/ATE208040T1/de

1995-02-27 Priority to DE69523492T priority patent/DE69523492T2/de

1995-03-01 Priority to JP08166095A priority patent/JP3541236B2/ja

1996-09-17 Priority to US08/715,097 priority patent/US5789260A/en

1998-06-15 Publication of IL108811A publication Critical patent/IL108811A/en

Links

238000003018 immunoassay Methods 0.000 title claims abstract description 11
239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 7
238000000034 method Methods 0.000 title claims description 18
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 34
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 34
210000002744 extracellular matrix Anatomy 0.000 claims abstract description 34
210000002700 urine Anatomy 0.000 claims abstract description 25
238000009739 binding Methods 0.000 claims abstract description 7
238000001514 detection method Methods 0.000 claims abstract description 7
230000027455 binding Effects 0.000 claims abstract description 6
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 38
238000012360 testing method Methods 0.000 claims description 18
239000000758 substrate Substances 0.000 claims description 11
102000004190 Enzymes Human genes 0.000 claims description 9
108090000790 Enzymes Proteins 0.000 claims description 9
239000007787 solid Substances 0.000 claims description 8
230000008859 change Effects 0.000 claims description 5
238000000159 protein binding assay Methods 0.000 claims description 4
238000005406 washing Methods 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 abstract description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
239000000427 antigen Substances 0.000 description 11
102000036639 antigens Human genes 0.000 description 11
108091007433 antigens Proteins 0.000 description 11
210000004027 cell Anatomy 0.000 description 9
210000002966 serum Anatomy 0.000 description 7
230000009266 disease activity Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
108010085895 Laminin Proteins 0.000 description 3
102000007547 Laminin Human genes 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
210000002469 basement membrane Anatomy 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
229920002971 Heparan sulfate Polymers 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
230000003172 anti-dna Effects 0.000 description 2
230000003460 anti-nuclear Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
108010082117 matrigel Proteins 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
108010008217 nidogen Proteins 0.000 description 2
230000008520 organization Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091016585 CD44 antigen Proteins 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010042086 Collagen Type IV Proteins 0.000 description 1
102000004266 Collagen Type IV Human genes 0.000 description 1
102000000989 Complement System Proteins Human genes 0.000 description 1
108010069112 Complement System Proteins Proteins 0.000 description 1
108010091326 Cryoglobulins Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
102100037369 Nidogen-1 Human genes 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108090000054 Syndecan-2 Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003429 anti-cardiolipin effect Effects 0.000 description 1
230000002583 anti-histone Effects 0.000 description 1
230000000781 anti-lymphocytic effect Effects 0.000 description 1
230000001405 anti-neuronal effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
210000000399 corneal endothelial cell Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
210000000871 endothelium corneal Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003237 epithelioid cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000000585 glomerular basement membrane Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
-1 test tubes Substances 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Rehabilitation Therapy (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

IL108811A 1994-03-01 1994-03-01 Immunoassay reagents, kits and methods IL108811A (en)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
IL108811A IL108811A (en)	1994-03-01	1994-03-01	Immunoassay reagents, kits and methods
EP95102740A EP0670495B1 (de)	1994-03-01	1995-02-27	Immunoassay-Reagenzien, Testsätze und Verfahren
AT95102740T ATE208040T1 (de)	1994-03-01	1995-02-27	Immunoassay-reagenzien, testsätze und verfahren
DE69523492T DE69523492T2 (de)	1994-03-01	1995-02-27	Immunoassay-Reagenzien, Testsätze und Verfahren
JP08166095A JP3541236B2 (ja)	1994-03-01	1995-03-01	イムノアッセイ試薬、キットおよび方法
US08/715,097 US5789260A (en)	1994-03-01	1996-09-17	Lupus disease immunoassay methods

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL108811A IL108811A (en)	1994-03-01	1994-03-01	Immunoassay reagents, kits and methods

Publications (2)

Publication Number	Publication Date
IL108811A0 IL108811A0 (en)	1994-06-24
IL108811A true IL108811A (en)	1998-06-15

Family

ID=11065863

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL108811A IL108811A (en)	1994-03-01	1994-03-01	Immunoassay reagents, kits and methods

Country Status (6)

Country	Link
US (1)	US5789260A (de)
EP (1)	EP0670495B1 (de)
JP (1)	JP3541236B2 (de)
AT (1)	ATE208040T1 (de)
DE (1)	DE69523492T2 (de)
IL (1)	IL108811A (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL120503A0 (en) *	1997-03-20	1997-07-13	Hadasit Med Res Service	Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
JP3989837B2 (ja) *	2000-11-22	2007-10-10	栄次松浦	抗ラミニン−１抗体の測定法およびその応用
US6905816B2 (en)	2000-11-27	2005-06-14	Intelligent Medical Devices, Inc.	Clinically intelligent diagnostic devices and methods
JP2005506839A (ja) *	2001-10-02	2005-03-10	ベクトン・ディキンソン・アンド・カンパニー	細胞外マトリックスおよび他の分子を使用する幹細胞の増殖および分化
US20040028675A1 (en) *	2001-12-07	2004-02-12	Zarlink Semiconductor Ab	Compositions for the treatment of lupus
CN113671195A (zh) *	2021-09-13	2021-11-19	迈克生物股份有限公司	抗双链dna抗体检测试剂盒及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5340720A (en) *	1989-11-29	1994-08-23	University Of Kansas	Methods of diagnosing and monitoring rheumatic diseases

1994
- 1994-03-01 IL IL108811A patent/IL108811A/en not_active IP Right Cessation
1995
- 1995-02-27 DE DE69523492T patent/DE69523492T2/de not_active Expired - Fee Related
- 1995-02-27 AT AT95102740T patent/ATE208040T1/de not_active IP Right Cessation
- 1995-02-27 EP EP95102740A patent/EP0670495B1/de not_active Expired - Lifetime
- 1995-03-01 JP JP08166095A patent/JP3541236B2/ja not_active Expired - Fee Related
1996
- 1996-09-17 US US08/715,097 patent/US5789260A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5789260A (en)	1998-08-04
JPH0835966A (ja)	1996-02-06
ATE208040T1 (de)	2001-11-15
IL108811A0 (en)	1994-06-24
EP0670495B1 (de)	2001-10-31
JP3541236B2 (ja)	2004-07-07
DE69523492D1 (de)	2001-12-06
EP0670495A1 (de)	1995-09-06
DE69523492T2 (de)	2002-07-04

Legal Events

Date	Code	Title
1998-11-26	FF	Patent granted
1999-04-11	KB	Patent renewed
2000-07-26	KB	Patent renewed
2000-08-31	KB	Patent renewed
2004-05-12	KB	Patent renewed
2008-03-23	KB	Patent renewed
2012-10-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
JP3040162B2 (ja)	2000-05-08	被検体のアッセイを妨害する物質の存在下における生体液中の被検体の測定法
US4200690A (en)	1980-04-29	Immunoassay with membrane immobilized antibody
CN102175871B (zh)	2014-05-07	双胶乳法测定血清或尿液中游离轻链的液体双试剂试剂盒
CA2437298A1 (en)	2001-08-30	Method for correlating blood coagulation activity with markers in body fluids, e.g. urine
JPS58213253A (ja)	1983-12-12	酵素／免疫螢光検定法
US6406860B1 (en)	2002-06-18	Method of detecting transmissible spongiform encephalopathies
FI95752B (fi)	1995-11-30	Määrityskitti ja -menetelmä kokonaisten solujen immunologiseen määritykseen
Brandt et al.	1990	Quantifying the MB isoenzyme of creatine kinase with the Abbott" IMx" immunoassay analyzer
CA1340575C (en)	1999-06-01	Article for performing immunological assays utilizing organic dyes and mehtods for producing and utilizing same
KR19980703302A (ko)	1998-10-15	글루타치온 s-트랜스퍼라제의 하나 또는 그 이상의 아이소엔자임 검출에 기초한 장기 상태 평가를 위한 쾌속 검정법
JPH03229153A (ja)	1991-10-11	リュウマチ病の診断に有用な特異的抗体または抗原の存在を検出する方法およびそれに用いられるテストキット
IL108811A (en)	1998-06-15	Immunoassay reagents, kits and methods
CN106324251A (zh)	2017-01-11	小片段BMG抗体的制备方法及β2‑微球蛋白检测试剂盒
AU721183B2 (en)	2000-06-22	Method for localization and quantitation of a substance in a biological sample
JPS60205367A (ja)	1985-10-16	抗‐エプスタイン‐バールビールス抗体の酵素‐免疫螢光試験法
RO105528B1 (ro)	1995-10-01	Metoda de analiza a antigenelor si anticorpilor in faza solida
CN102246044B (zh)	2015-01-14	体液中ifi 16的检测
JP2004069672A (ja)	2004-03-04	酸化アポリポタンパク質ａｉ及びそれを含有する酸化リポタンパク質の測定法及びキット
RU2818115C1 (ru)	2024-04-24	Способ определения индекса авидности аутоантител в сыворотке крови человека на гидрогелевых биочипах
EP0182896A1 (de)	1986-06-04	Diagnosetestverfahren zum nachweis von mit medikamenten induziertem lupus erythemotosus verbundenen antikörpern
RU2157540C2 (ru)	2000-10-10	Способ определения или обнаружения повреждения органа-донора после ксенотрансплантации на основе анализа веществ, полученных из органа-донора
RU2180117C1 (ru)	2002-02-27	Способ оценки сенсибилизации к химическим соединениям
JP2019190883A (ja)	2019-10-31	新規肺がんマーカー
JP3309900B2 (ja)	2002-07-29	抗ｆｋｂｐ１２自己抗体の検出方法
JPH03134567A (ja)	1991-06-07	抗リン脂質抗体結合用担体、それを使用する免疫学的測定法およびキット